Biogen Marks Time As Biosimilars Business Keeps Ticking Over

While biosimilars updates were thin on the ground as Biogen reported its full-year results, the segment nevertheless reported growth in 2024. Meanwhile, the firm also offered some comments on how it saw generic and biosimilar competition to its Tecfidera and Tysabri multiple sclerosis brands playing out this year.